IntegenX designs, manufactures and markets automation systems facilitating reliable micro sample preparation and analysis.
IntegenX, Inc. designs, manufactures, and markets automation systems that enable reliable microsample preparation and analysis for the life sciences. It offers Apollo 100, a platform that allows the processing of DNA sequencing reactions; Apollo 200, an integrated sample preparation system for human DNA identification; microfluidics for DNA sequencing, molecular diagnostics, and human identification applications; and Apollo 324 system, a benchtop robotic workstation that automates the construction of DNA fragment libraries for next-generation sequencing. The company was formerly known as Microchip Biotechnologies, Inc. and changed its name to IntegenX, Inc. in March 2010. The company was incorporated in 2003 and is based in Pleasanton, California.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 22, 2014 | Debt Financing | $10M | 1 | — | — | Detail |
Dec 13, 2011 | Series C | $40M | 1 | — | — | Detail |
Nov 12, 2009 | Series B | $18.10M | 1 | — | — | Detail |
Aug 29, 2006 | Series A | $4.50M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Horizon Technology Finance | — | Debt Financing |
Rona Syndicates | — | Series C |